glp 1 agonist for weight loss Medical Solutions GLP-1 Agonists - What is
Description
Ethics declarations Competing Interests The authors declare no competing interests
With GLP-1 access and adherence on such shaky ground, obesity and diabetes experts are doubling down on the perils of taking the medications without a comprehensive engagement system backing them up
In both trials, there was no difference in rates of nonfatal myocardial infarction and cardiovascular death between GLP-1 RA treated patients and placebo
Hamman JH, Enslin GM, Kotze AF
